25 Posts From ASCO24 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31st to June 4th 2024.
Our team at OncoDaily selected 25 from ASCO24 that you should not miss. Check out the end of the post for highlights for individual days.
To ALL those we have lost to cancer…and to our survivors as well, in your honor, we will continue to fight cancer and comfort those who suffer from it…all over the world.
Excited to present my poster this morning at the American Society of Clinical Oncology (ASCO24) annual meeting and about an important area of research on brain cancer (MDM4-amplified high-grade glioma) that needs much more worldwide attention.
- June 1, 2024
- Poster session 9:00 am-Noon
- Hall A
- Central Nervous System Tumors
- Abstract 2080
- Poster Board 379
Therapeutic insights for the aggressive subset of High-Grade Gliomas (HGG) driven by chromosome 1q32 MDM4-containing amplicon and unmethylated MGMT.
Our work at Brown and Legorreta Cancer Centers was conducted in collaboration with Caris Life Sciences.
In Oncology/Neuro-Oncology there is a significant unmet need in GBM with MDM4 amplification. These MDM4-amplified GBM’s:
- Represent 5-10% of GBMs,
- Involve MDM4 as a potent driver (blocks p53 pathway, suppresses T-cell killing, is co-amplified with other targetable drivers),
- There are no FDA-approved drugs in 2024 or any being tested against the target (either MDM4-specific or dual MDM2-MDM4) in GBM.
MDM4 is associated with worse outcomes regardless of MGMT methylation status, and I previously presented worse outcomes across tumor types (El-Deiry et al., ASCO, 2022) including after immune checkpoint blockade.
We now recognize genetically linked targetable associated amplified genes that are overexpressed, coming from the same amplicon. These include kinase PIK3C2B and phosphatase PPP1R15B, among others. There are opportunities for combinations with other agents active in GBM.
I would be very happy to collaborate with anyone interested in supporting progress on this deadly disease where our insights suggest novel therapy strategies to help patients with aggressive MDM4-amplified GBMs.
LBA out: Phase 3 EVOKE-01 study. Sacituzumab vs Docetaxel… and… no better! Underwhelming results.
One subgroup to note ‘Clinically meaningful improvement of OS was noted in patients without response to prior IO’. 383 patients OS 8.3 vs 11.8 for these patients HR 0.75 (0.58–0.97).
We are overwhelmed with support and love and more importantly, excitement about working together to take our recommendations forward from The Lancet Commission on Women, Power, and Cancer!
Special thanks to the American Society of Clinical Oncology (ASCO), Dr. Julie Gralow whose unwavering support and wise counsel helped move this forward – and ASCO President Dr. Lynn Schucter who came to our African launch in Senegal and invited us to contribute to a session at this year’s ASCO event in Chicago.
Women lifting up women – this is the way it’s done! Read the report. Join the movement.
A wonderful evening with my AORTIC AFRICA family. Many issues raised around research in Africa. Comforting that organizations like ASCO and NCI Research Center for Cancer Research are actively funding and creating opportunities for researchers in Africa.
One of the most important presentations of ASCO24: expansion cohorts from Translational Breast Cancer Research Consortium TBCRC048, presented by Nadine Tung.
Among patients with Metastatic Breast Cancer, olaparib achieved:
– ORR 76% in gPALB2 mutation carriers
– ORR 37% in sBRCA mutation carriers
Terrific effort from The Translational Breast Cancer Research Consortium (make sure to follow for more!)
GIANT trial in more than 70 years/vulnerable Pancreatic ductal adenocarcinoma (PDAC) American Society of Clinical Oncology 2024 (ASCO24) as by geriatric assess.
- Important to remember most on PDAC trials less than 70 years.
- Dose modified Gemcitabine plus nab-Paclitaxel (GnP) versus 5‐Fluorouracil (5FU) liposomal irinotecan.
- Sobering med Overall Survival (OS) by Intention-To-Treat (ITT) 4.7 versus 4.4 months.
- Need to identify who can benefit and discuss with patients.
Every Patient is Unique, Every Story Matters! At ASCO24, we’re reminded of the diverse and inspiring journeys that ignite our passion for oncology.
Each patient’s story is a powerful testament to resilience and hope. Let’s continue to share, listen, and learn from each unique experience.
Glad to see Dr. Philip Kantoff receive the ASCO24 Excellence in Teaching Award this past weekend.
Dr. Kantoff has inspired countless scientists, fellows, and faculty, all in service of improving the lives of cancer patients and their families.
Management of pregnancy with lung cancer
- No 1st trimester
- Dose according to actual body weight
- Maintain dose intensity
- Don’t increase/decrease the dose
- No chemotherapy at 35-37 of gestation
- Minimum 3-week interval between the last cycle delivery
- Avoid IO in 2/3 trimester
Wanted to share some photos from my chat with Penn Medicine breast cancer researcher Dr. DeMichelle and Dr. Rathmell at the ASCO24 Annual Meeting.
We had a thoughtful discussion on how public investment can accelerate progress in oncology.
We are excited to announce the esteemed winners of the Yvonne Award 2024 by OncoDaily, designed to recognize young innovators and leaders advancing cancer care.
Yvonne Award in the Breakthrough Research category
Vinod Balachandran
This award recognizes exceptional contributions that have the potential to transform cancer care and exemplify the strength and enduring impact of innovative research. Celebrating researchers who have pioneered significant discoveries and advancements in oncology, dramatically improving patient outcomes.
Yvonne Award in the Leadership category
Asya Agulnik
This award recognizes individuals who have exhibited exceptional leadership qualities in oncology. Recipients are commended for their visionary approach, guiding teams and institutions towards notable achievements in cancer treatment and care. The award celebrates their dedication, integrity, and significant contributions to advancing excellence in patient outcomes.
Yvonne Award in the Global Oncology category
Haimanot Kasahun Alemu
The award is granted to emerging leaders who have demonstrated exceptional talent and dedication in oncology on a global scale. Recipients are recognized for their substantial contributions to reducing disparities in cancer care worldwide, creating sustainable changes, and promoting equal access to treatments across communities.
Yvonne Award in the Challenging the Status Quo category
Pashtoon Kasi and Erica Tsang
The award is presented to individuals who have courageously challenged conventional practices, introducing groundbreaking approaches that transform cancer care. This award celebrates resilient and innovative leaders who inspire change and foster advancements in oncology treatment and patient care.
Yvonne Award in the Voice of Oncology category
Vivek Subbiah
This is a special award presented to the most cited author by OncoDaily within the previous year. The award honors individuals who have significantly influenced oncology through their advocacy and contributions. This award recognizes those whose work is widely acknowledged and cited within the oncology community. Recipients are celebrated for raising awareness, shaping public opinion, and driving conversations that improve cancer care. Their voices catalyze change and progress in oncology.
Yvonne Award in the Community Oncology category
Foluke Sarimiye and Abeid Athman Omar
The award is granted to individuals who have made outstanding contributions to enhancing cancer care within their communities. Recipients are recognized for their tireless efforts in improving the quality of life and accessibility of treatments for patients, ensuring effective care is available to all segments of society.
Yvonne Award in the Mentorship category
Anna Spreafico and Maria Babak
This award honors mentors who have shown exceptional dedication and guidance in the field of oncology. Recipients are celebrated for profoundly influencing the careers and development of the next generation of oncology professionals, nurturing growth, and fostering leadership within the community.
At ASCO24, an annual meeting for oncology professionals, Dr. Karen Knudsen and Albert Bourla meet to discuss how cancer disproportionately impacts ethnic/racial groups.
To change these odds, this three-year initiative with Pfizer is addressing disparities in cancer care, to improve health outcomes in medically underrepresented.
Investing in the next generation of oncologists is crucial for the future of cancer research. At ASCO24, let’s continue to support and mentor young talents who will drive innovation and breakthroughs in oncology. Together, we can achieve more!
Not every day that you get to celebrate a years-long survival advantage in the treatment of small cell lung cancer!
Mind-blowing to see the median overall survival for limited stage SCLC approach the oncologically conventional 5-year milestone at ASCO24.
American Society of Clinical Oncology (ASCO) Regional Councils Meeting at ASCO24. All volunteers helping to make our society more in tune with specific needs of different geographical regions.
There is a lot to learn and synergise between us the beat cancer globally!
Today, ECO President Csaba Dégi met with Arman Kacharian, Head of the Innovations Expert Group at the Ministry of Health of Ukraine.
Ukrainian cancer specialists at the ASCO Congress shared how their Workforce and Patient care needs can be supported by international colleagues.
ECO and ASCO’s long-term commitment to supporting cancer professionals and patients in Ukraine remains intact. Read our ECO report on Cancer Medicines Shortages During the War in Ukraine.
ADRIATIC – another practice changing trial ASCOLung! Consolidation durvalumab post-chemorads in LS-SCLC led to an improvement of nearly 2 YEARS in mOS compared to placebo!
55.9 vs 33.4 months, HR 0.73 and 7 months improvement in mPFS.
SCRI’s David R. Spigel presented important updates from the ADRIATIC study for limited stage small cell lung cancer.
An exciting day in lung cancer with results from LAURA study as well as ADRIATIC study, proving again that Today’s Clinical Trials are Tomorrow’s Therapies.
ESOPEC- Practice shifting trial
Patients with resectable, locally advanced, esophagus/GEJ adenocarcinoma Randomized Peri-op FLOT (FLOT4) vs Pre-operative chemoradiation (CROSS) Congrats to the study investigators! Let’s dive in!
ASCO24 Plenary Abstract 3
Dr Joseph Greer presents positive large study of Early Palliative Telemedicine Care for NSCLC N=1250 patients and caregivers. Monthly tele- visits vs in person. Improvement in QOL at 24 weeks.
Kudos to investigators for a study completed during COVID. Proof of concept but can it be replicated?, can it be scaled up? is it an US health access problem? What about the almost 1,000 pts who did not agree to the study? Role of tech divide?
Exciting News! I’m thrilled to share that TAPUR study on the antitumor activity of Pertuzumab+Trastuzumab in advanced solid tumors with ERBB2/3 alterations has been presented at the 2024 ASCO Annual Meeting!
This research, conducted with the incredible team at Trinity Health MI (Ann Arbor) and other sites accross the nation, shows promising results with a disease control rate of 57% and an objective response rate of 29%.
Onward to more advancements in cancer treatment!
The Netherlands Cancer Institute
Immunotherapy before surgery for patients with metastatic melanoma appears to be successful as 59% of patients responds so well that adjuvant treatment is no longer needed, show the results of the NADINA trial presented at ASCO24 today by Christian Blank.
ASCO24 has been such a wonderful experience. The research presentations, patient stories, and array of professionals are truly inspiring. With each step, I am reminded of the wide gaps in cancer control between the global north and south.
I look forward to a time we can provide the infrastructure, organization, resources and content to host such gatherings at the same scale in Africa.
Thank you for being part of this tremendous ASCO24 session with Kimryn Rathmell. This was a robust discussion on topics ranging from the National Cancer Plan, research funding, clinical trial diversity and access, workforce issues, and more.
Watch full session.
Highlights from Day 1
Highlights from Day 2
Highlights from Day 3
Highlights from Day 4
Highlights from Day 5